1,558
Views
40
CrossRef citations to date
0
Altmetric
Original Articles

Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer

, , , , , , , , , , , & show all
Pages 1398-1404 | Received 03 May 2013, Accepted 29 May 2013, Published online: 09 Sep 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Janna E. van Timmeren, Ralph T. H. Leijenaar, Wouter van Elmpt, Bart Reymen & Philippe Lambin. (2017) Feature selection methodology for longitudinal cone-beam CT radiomics. Acta Oncologica 56:11, pages 1537-1543.
Read now
Evelyn E. C. de Jong, Wouter van Elmpt, Otto S. Hoekstra, Harry J. M. Groen, Egbert F. Smit, Ronald Boellaard, Philippe Lambin & Anne-Marie C. Dingemans. (2017) Quality assessment of positron emission tomography scans: recommendations for future multicentre trials. Acta Oncologica 56:11, pages 1459-1464.
Read now
Cai Grau, Jens Overgaard, Morten Høyer, Kari Tanderup, Jacob Christian Lindegaard & Ludvig Paul Muren. (2015) Biology-guided adaptive radiotherapy (BiGART) is progressing towards clinical reality. Acta Oncologica 54:9, pages 1245-1250.
Read now
Marius Røthe Arnesen, Ingerid Skjei Knudtsen, Bernt Louni Rekstad, Karsten Eilertsen, Einar Dale, Kjersti Bruheim, Åslaug Helland, Ayca Muftuler Løndalen, Taran Paulsen Hellebust & Eirik Malinen. (2015) Dose painting by numbers in a standard treatment planning system using inverted dose prescription maps. Acta Oncologica 54:9, pages 1607-1613.
Read now
Ludvig P. Muren, Mika Teräs & Juhani Knuuti. (2014) NACP 2014 and the Turku PET symposium: The interaction between therapy and imaging. Acta Oncologica 53:8, pages 993-996.
Read now

Articles from other publishers (35)

Jina Park, Wenjing Hu, Ick Hoon Jin, Hao Liu & Yong Zang. (2023) A Bayesian adaptive biomarker stratified phase II randomized clinical trial design for radiotherapies with competing risk survival outcomes. Statistical Methods in Medical Research.
Crossref
Feng Pan, Li Feng, Baocai Liu, Yue Hu & Qian Wang. (2023) Application of radiomics in diagnosis and treatment of lung cancer. Frontiers in Pharmacology 14.
Crossref
Parisa Forouzannezhad, Dominic Maes, Daniel S. Hippe, Phawis Thammasorn, Reza Iranzad, Jie Han, Chunyan Duan, Xiao Liu, Shouyi Wang, W. Art Chaovalitwongse, Jing Zeng & Stephen R. Bowen. (2022) Multitask Learning Radiomics on Longitudinal Imaging to Predict Survival Outcomes following Risk-Adaptive Chemoradiation for Non-Small Cell Lung Cancer. Cancers 14:5, pages 1228.
Crossref
Carol Oliveira, Florian Amstutz, Diem Vuong, Marta Bogowicz, Martin Hüllner, Robert Foerster, Lucas Basler, Christina Schröder, Eric I. Eboulet, Miklos Pless, Sandra Thierstein, Solange Peters, Sven Hillinger, Stephanie Tanadini-Lang & Matthias Guckenberger. (2021) Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging. EJNMMI Research 11:1.
Crossref
Hanna Muenzfeld, Claus Nowak, Stefanie Riedlberger, Alexander Hartenstein, Bernd Hamm, Paul Jahnke & Tobias Penzkofer. (2021) Intra-scanner repeatability of quantitative imaging features in a 3D printed semi-anthropomorphic CT phantom. European Journal of Radiology 141, pages 109818.
Crossref
Reyhaneh Manafi-Farid, Najme Karamzade-Ziarati, Reza Vali, Felix M. Mottaghy & Mohsen Beheshti. (2021) 2-[18F]FDG PET/CT radiomics in lung cancer: An overview of the technical aspect and its emerging role in management of the disease. Methods 188, pages 84-97.
Crossref
Malene M. Clausen, Ivan R. Vogelius, Andreas Kjær & Søren M. Bentzen. (2020) Multiple Testing, Cut-Point Optimization, and Signs of Publication Bias in Prognostic FDG–PET Imaging Studies of Head and Neck and Lung Cancer: A Review and Meta-Analysis. Diagnostics 10:12, pages 1030.
Crossref
Qingjin Qin, Anhui Shi, Ran Zhang, Qiang Wen, Tianye Niu, Jinhu Chen, Qingtao Qiu, Yidong Wan, Xiaorong Sun & Ligang Xing. (2020) Cone‐beam CT radiomics features might improve the prediction of lung toxicity after SBRT in stage I NSCLC patients. Thoracic Cancer 11:4, pages 964-972.
Crossref
Turkey Refaee, Guangyao Wu, Abdallah Ibrahim, Iva Halilaj, Ralph T.H. Leijenaar, William Rogers, Hester A. Gietema, Lizza E.L. Hendriks, Philippe Lambin & Henry C. Woodruff. (2020) The Emerging Role of Radiomics in COPD and Lung Cancer. Respiration 99:2, pages 99-107.
Crossref
Urmi Chatterji. 2020. Oxidative Stress in Lung Diseases. Oxidative Stress in Lung Diseases 385 409 .
Catherine Cheze Le Rest & Roland Hustinx. (2019) Are radiomics ready for clinical prime-time in PET/CT imaging?. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 63:4.
Crossref
Chiesa-Estomba, Echaniz, Larruscain, Gonzalez-Garcia, Sistiaga-Suarez & Graña. (2019) Radiomics and Texture Analysis in Laryngeal Cancer. Looking for New Frontiers in Precision Medicine through Imaging Analysis. Cancers 11:10, pages 1409.
Crossref
Michael Schwier, Joost van Griethuysen, Mark G. Vangel, Steve Pieper, Sharon Peled, Clare Tempany, Hugo J. W. L. Aerts, Ron Kikinis, Fiona M. Fennessy & Andriy Fedorov. (2019) Repeatability of Multiparametric Prostate MRI Radiomics Features. Scientific Reports 9:1.
Crossref
Rebecca Bütof & Esther G. C. Troost. (2018) The role of functional imaging in lung cancer. Clinical and Translational Imaging 6:6, pages 441-447.
Crossref
Yonglin Pu, James X. Zhang, Haiyan Liu, Daniel Appelbaum, Jianfeng Meng & Bill C. Penney. (2018) Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging. European Journal of Nuclear Medicine and Molecular Imaging 45:12, pages 2079-2092.
Crossref
Pierre Lovinfosse, Mathieu Hatt, Dimitris Visvikis & Roland Hustinx. (2018) Heterogeneity analysis of 18F-FDG PET imaging in oncology: clinical indications and perspectives. Clinical and Translational Imaging 6:5, pages 393-410.
Crossref
Venus Sosa Iglesias, Lorena Giuranno, Ludwig J. Dubois, Jan Theys & Marc Vooijs. (2018) Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?. Frontiers in Oncology 8.
Crossref
Sara Carvalho, Ralph T. H. Leijenaar, Esther G. C. Troost, Janna E. van Timmeren, Cary Oberije, Wouter van Elmpt, Lioe-Fee de Geus-Oei, Johan Bussink & Philippe Lambin. (2018) 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) – A prospective externally validated study. PLOS ONE 13:3, pages e0192859.
Crossref
M. Lazzeroni, J. Uhrdin, S. Carvalho, W. van Elmpt, P. Lambin, A. Dasu, P. Wersäll & I. Toma-Dasu. (2018) Evaluation of third treatment week as temporal window for assessing responsiveness on repeated FDG-PET-CT scans in Non-Small Cell Lung Cancer patients. Physica Medica 46, pages 45-51.
Crossref
Hyung-Jun Im, Tyler Bradshaw, Meiyappan Solaiyappan & Steve Y. Cho. (2017) Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?. Nuclear Medicine and Molecular Imaging 52:1, pages 5-15.
Crossref
Liting Shi, Yaoyao He, Zilong Yuan, Stanley Benedict, Richard Valicenti, Jianfeng Qiu & Yi Rong. (2018) Radiomics for Response and Outcome Assessment for Non-Small Cell Lung Cancer. Technology in Cancer Research & Treatment 17, pages 153303381878278.
Crossref
Brittany Z. Dashevsky, Chenpeng Zhang, Li Yan, Cindy Yuan, Lingyun Xiong, Yongmei Liu, Haiyan Liu, Feng-Ming Spring Kong & Yonglin Pu. (2017) Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation. European Journal of Hybrid Imaging 1:1.
Crossref
Lidija Antunovic, Francesca Gallivanone, Martina Sollini, Andrea Sagona, Alessandra Invento, Giulia Manfrinato, Margarita Kirienko, Corrado Tinterri, Arturo Chiti & Isabella Castiglioni. (2017) [18F]FDG PET/CT features for the molecular characterization of primary breast tumors. European Journal of Nuclear Medicine and Molecular Imaging 44:12, pages 1945-1954.
Crossref
Janna E. van Timmeren, Ralph T.H. Leijenaar, Wouter van Elmpt, Bart Reymen, Cary Oberije, René Monshouwer, Johan Bussink, Carsten Brink, Olfred Hansen & Philippe Lambin. (2017) Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. Radiotherapy and Oncology 123:3, pages 363-369.
Crossref
M. Sollini, L. Cozzi, L. Antunovic, A. Chiti & M. Kirienko. (2017) PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology. Scientific Reports 7:1.
Crossref
Philippe Lambin, Jaap Zindler, Ben G.L. Vanneste, Lien Van De Voorde, Daniëlle Eekers, Inge Compter, Kranthi Marella Panth, Jurgen Peerlings, Ruben T.H.M. Larue, Timo M. Deist, Arthur Jochems, Tim Lustberg, Johan van Soest, Evelyn E.C. de Jong, Aniek J.G. Even, Bart Reymen, Nicolle Rekers, Marike van Gisbergen, Erik Roelofs, Sara Carvalho, Ralph T.H. Leijenaar, Catharina M.L. Zegers, Maria Jacobs, Janita van Timmeren, Patricia Brouwers, Jonathan A. Lal, Ludwig Dubois, Ala Yaromina, Evert Jan Van Limbergen, Maaike Berbee, Wouter van Elmpt, Cary Oberije, Bram Ramaekers, Andre Dekker, Liesbeth J. Boersma, Frank Hoebers, Kim M. Smits, Adriana J. Berlanga & Sean Walsh. (2017) Decision support systems for personalized and participative radiation oncology. Advanced Drug Delivery Reviews 109, pages 131-153.
Crossref
Ruben T. H. M. Larue, Lien Van De Voorde, Maaike Berbée, Wouter J. C. van Elmpt, Ludwig J. Dubois, Kranthi M. Panth, Sarah G. J. A. Peeters, Ann Claessens, Wendy M. J. Schreurs, Marius Nap, Fabiënne A. R. M. Warmerdam, Frans L. G. Erdkamp, Meindert N. Sosef & Philippe Lambin. (2016) A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer 16:1.
Crossref
Xiaonan Ma, Jenifer Siegelman, David S. Paik, James L. Mulshine, Samantha St. Pierre & Andrew J. Buckler. (2016) Volumes Learned. Academic Radiology 23:9, pages 1190-1198.
Crossref
Seong-Jang Kim, Phillip J. Koo & Samuel Chang. (2016) Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients. Cancer Chemotherapy and Pharmacology 77:4, pages 723-731.
Crossref
Samuel ChangSeong-Jang Kim. (2016) Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters. Cancer Biotherapy and Radiopharmaceuticals 31:1, pages 1-6.
Crossref
Chintan Parmar, Patrick Grossmann, Derek Rietveld, Michelle M. Rietbergen, Philippe Lambin & Hugo J. W. L. Aerts. (2015) Radiomic Machine-Learning Classifiers for Prognostic Biomarkers of Head and Neck Cancer. Frontiers in Oncology 5.
Crossref
Kranthi Marella Panth, Ralph T.H. Leijenaar, Sara Carvalho, Natasja G. Lieuwes, Ala Yaromina, Ludwig Dubois & Philippe Lambin. (2015) Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells. Radiotherapy and Oncology 116:3, pages 462-466.
Crossref
Ralph T.H. Leijenaar, Georgi Nalbantov, Sara Carvalho, Wouter J.C. van Elmpt, Esther G.C. Troost, Ronald Boellaard, Hugo J.W.L Aerts, Robert J. Gillies & Philippe Lambin. (2015) The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis. Scientific Reports 5:1.
Crossref
D Thorwarth. (2015) Functional imaging for radiotherapy treatment planning: current status and future directions—a review. The British Journal of Radiology 88:1051, pages 20150056.
Crossref
Iuliana Toma-Dasu, Johan Uhrdin, Marta Lazzeroni, Sara Carvalho, Wouter van Elmpt, Philippe Lambin & Alexandru Dasu. (2015) Evaluating Tumor Response of Non-Small Cell Lung Cancer Patients With 18F-Fludeoxyglucose Positron Emission Tomography: Potential for Treatment Individualization. International Journal of Radiation Oncology*Biology*Physics 91:2, pages 376-384.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.